title: Erythropoietin production after kidney transplantation.
abstract: We studied production of erythropoietin (EPO) in long-term renal allograft recipients with posttransplant erythrocytosis (PTE). Among 951 recipients we found 74 patients with persistent elevation of hematocrit (Htc) value (female > 50%, male > 55%). However, only 63.5% of them had increased red-cell mass ( = "true" erythrocytosis). In all recipients with PTE known causes of secondary erythrocytosis were not found. EPO titer in peripheral blood was significantly higher in recipients with PTE (median 13.5 mIU/mL, range: 0.1-71.5 mIU/mL) as compared to healthy blood donors (median 5.75 mIU/mL, range: 0.1-19.5 mIU/mL) but not different from the group of renal allograft recipients without PTE (median 13.0, range 0.1-71.7 mIU/mL). However, EPO level measured in pretransplant sera was significantly higher in patients who developed PTE (median 16.4 mIU/mL, range: 1.0-281.2 mIU/mL) than in recipients without PTE (median 8.3, range: 1.0-50.3 mIU/mL). A significant difference in EPO level between systemic and effluent blood from native kidneys was found in 6 out of 14 recipients with PTE who underwent catheterization. After phlebotomy patients with PTE responded with higher increase in peak EPO titer than healthy blood donors (527 +/- 473% versus 194.5 +/- 44.2%, p < 0.05). Our results suggest that PTE develops spontaneously due to increased EPO production. Despite elevated EPO levels, regulation of EPO release remains preserved.
authors.affiliation: Transplantation Institute, Warsaw Medical School, Poland.
authors.forename: Z
authors.initials: Z
authors.lastname: Gaciong
authors.forename: K
authors.initials: K
authors.lastname: Koziak
authors.forename: I
authors.initials: I
authors.lastname: Jarzyło
authors.forename: K
authors.initials: K
authors.lastname: Ludwicki
authors.forename: S
authors.initials: S
authors.lastname: Malanowska
authors.forename: L
authors.initials: L
authors.lastname: Paczek
authors.forename: J
authors.initials: J
authors.lastname: Szmidt
authors.forename: J
authors.initials: J
authors.lastname: Wałaszewski
authors.forename: M
authors.initials: M
authors.lastname: Lao
mesh_terms: D000328:Adult; D001782:Blood Donors; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006400:Hematocrit; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000097:blood*; D011183:Postoperative Complications; D012016:Reference Values; D012189:Retrospective Studies; D012727:Sex Characteristics
chemical_list: D007166:Immunosuppressive Agents; D004921:Erythropoietin